Molecular based therapies targeting epidermal growth factor receptor (EGFR) mutants [2,3] or ALK rearrangements [4] were shown to improve the outcome within well-defined subgroups of non-squamous cell carcinoma patients. This evidence concerns the gene EGFR and squamous cell carcinoma.